keyword
MENU ▼
Read by QxMD icon Read
search

Formoterol

keyword
https://www.readbyqxmd.com/read/28822448/-warning-symptoms-of-asthma-attack-and-asthma-self-management-a-national-asthma-control-survey-from-china
#1
J T Lin, W Q Wang, X Zhou, C Z Wang, M Huang, S X Cai, P Chen, Q C Lin, J Y Zhou, Y H Gu, Y D Yuan, D J Sun, X H Yang, L Yang, J M Huo, Z C Chen, P Jiang, J Zhang, X W Ye, H G Liu, H P Tang, R Y Liu, C T Liu, W Zhang, C P Hu, Y Q Chen, X J Liu, L M Dai, W Zhou, Y J Huang, J Y Xu
Objective: To investigate warning symptoms of asthma attack and evaluate asthma self-management status of asthma patients in urban China. Methods: A multi-center, cross-sectional, questionnaire-based survey was carried out from 30 general hospitals dispersed in 30 provinces of mainland China (except for Tibet) during Oct 2015 to May 2016. Information of frequency and warning symptoms of asthma attack, the time from warning symptoms to asthma attack, the impact of asthma attack and asthma self-management were collected from asthma patients of outpatient department...
August 8, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28821260/24-h-bronchodilation-and-inspiratory-capacity-improvements-with-glycopyrrolate-formoterol-fumarate-via-co-suspension-delivery-technology-in-copd
#2
Colin Reisner, Gregory Gottschlich, Faisal Fakih, Andras Koser, James Krainson, Luis Delacruz, Samir Arora, Gregory Feldman, Krishna Pudi, Shahid Siddiqui, Chad Orevillo, Andrea Maes, Earl St Rose, Ubaldo Martin
BACKGROUND: Symptoms of chronic obstructive pulmonary disease may vary throughout the day and it is important that therapeutic approaches provide 24-h symptom control. We report the results of two phase IIIb crossover studies, PT003011 and PT003012, investigating the 24-h lung function profile of GFF MDI (glycopyrrolate/formoterol fumarate 18/9.6 μg delivered using innovative co-suspension delivery technology) administered twice daily. METHODS: Patients with moderate-to-very severe chronic obstructive pulmonary disease received 4 weeks' treatment with each of GFF MDI, placebo MDI, and open-label tiotropium (PT003011 only)...
August 18, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28814858/spotlight-on-glycopyrronium-formoterol-fumarate-inhalation-aerosol-in-the-management-of-copd-design-development-and-place-in-therapy
#3
REVIEW
Santosh Dhungana, Gerard J Criner
Long-acting bronchodilators are the mainstay of the treatment of COPD. With the advent of several combination inhalers with long-acting antimuscarinic agents (LAMAs) and long-acting beta agonists (LABAs), the choice of therapy in the treatment of COPD has been ever expanding. With the focus of COPD management shifting from FEV1-based treatment escalation to symptoms and risk-based treatment, we are seeing a paradigm shift in COPD treatment with early introduction of LAMA-LABA combination as a single inhaler...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28757318/new-treatment-option-for-copd-two-long-acting-bronchodilators-in-a-single-metered-dose-inhaler
#4
REVIEW
Timothy H Self, Samantha Ellingson
Combination long-acting inhaled bronchodilators are central to the management of moderate to very severe chronic obstructive pulmonary disease (COPD) patients. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta2 agonist (LABA). In randomized controlled trials, this LAMA/LABA combination in a metered dose inhaler (MDI) was shown to be effective in improving pulmonary function and quality of life. Clinicians now have the availability of three delivery systems for LAMA/LABA therapy, including MDI, dry-powder inhaler, and Soft Mist inhaler...
July 27, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28757256/proposed-algorithm-for-healthcare-professionals-based-on-product-characteristics-and-in-vitro-performances-in-different-use-conditions-using-formoterol-based-marketed-products-for-inhalation
#5
Nathalie Wauthoz, Ismaël Hennia, Bieke Dejaeger, Susana Ecenarro, Karim Amighi
Healthcare professionals require an easy algorithm for selecting the most appropriate inhalation product for each patient at the beginning of a treatment. As a case study, we selected five marketed formoterol products: Foradil(®) and Formagal(®), capsule-based dry powder inhalers (DPIs), Novolizer(®) Formoterol and Oxis(®), reservoir-based DPIs and Formoair(®), a pressurized metered dose inhaler. We generated an algorithm based on device properties (i.e. device handling, feedback and remaining dose/end of product indication) and in vitro aerodynamic performances (i) along the product use life in optimal conditions, (ii) at different airflows and (iii) after exposing pre-loaded doses to 40°C and 75% relative humidity for 4h...
July 27, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28754379/%C3%AE-2-adrenoceptor-induced-modulation-of-transglutaminase-2-transamidase-activity-in-cardiomyoblasts
#6
Falguni S Vyas, Carl P Nelson, Fiona Freeman, David J Boocock, Alan J Hargreaves, John M Dickenson
Tissue transglutaminase 2 (TG2) is modulated by protein kinase A (PKA) mediated phosphorylation: however, the precise mechanism(s) of its modulation by G-protein coupled receptors coupled to PKA activation are not fully understood. In the current study we investigated the potential regulation of TG2 activity by the β2-adrenoceptor in rat H9c2 cardiomyoblasts. Transglutaminase transamidation activity was assessed using amine-incorporating and protein cross-linking assays. TG2 phosphorylation was determined via immunoprecipitation and Western blotting...
July 25, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28744115/bronchodilator-efficacy-of-extrafine-glycopyrronium-bromide-the-glyco-2-study
#7
Dave Singh, Mario Scuri, Sara Collarini, Stefano Vezzoli, Fabrizia Mariotti, Annamaria Muraro, Daniela Acerbi
An extrafine formulation of the long-acting muscarinic antagonist glycopyrronium bromide (GB) is in development for chronic obstructive pulmonary disease (COPD), in combination with beclometasone dipropionate and formoterol fumarate - a "fixed triple". This two-part study was randomized, double blind, placebo controlled in patients with moderate-to-severe COPD: Part 1: single-dose escalation, GB 12.5, 25, 50, 100 or 200 μg versus placebo; Part 2: repeat-dose (7-day), four-period crossover, GB 12.5, 25 or 50 μg twice daily (BID) versus placebo, with an open-label extension in which all patients received tiotropium 18 μg once daily...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28740376/fluticasone-propionate-formoterol-for-copd-management-a-randomized-controlled-trial
#8
A Papi, D Dokic, W Tzimas, I Mészáros, A Olech-Cudzik, Z Koroknai, K McAulay, S Mersmann, P S Dalvi, T Overend
PURPOSE: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. PATIENTS AND METHODS: COPD patients with forced expiratory volume in 1 s (FEV1) ≤50% predicted and ≥1 moderate/severe COPD exacerbation in the last 12 months were randomized to FP/FORM 500/20 or 250/10 µg bid, or formoterol (FORM) 12 µg bid for 52 weeks. The primary outcome was the annualized rate of moderate/severe COPD exacerbations. RESULTS: In total, 1,765 patients were randomized...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28732831/initiating-or-changing-to-a-fixed-dose-combination-of-fluticasone-propionate-formoterol-over-fluticasone-propionate-salmeterol-a-real-life-effectiveness-and-cost-impact-evaluation
#9
Simon Wan Yau Ming, John Haughney, Iain Small, Stephanie Wolfe, John Hamill, Kevin Gruffydd-Jones, Cathal Daly, Joan B Soriano, Elizabeth Gardener, Derek Skinner, Martina Stagno d'Alcontres, David B Price
OBJECTIVE: Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment could positively influence the economic burden of this disease. Fluticasone propionate/Formoterol (FP/FOR) may be as effective as Fluticasone Salmeterol (FP/SAL). We evaluated non-inferiority of asthma control in terms of the proportion of patients free from exacerbations, and conducted a cost impact analysis. METHODS: This historical, matched cohort database study evaluated two treatment groups in the Optimum Patient Care Research Database in the UK: 1) an FP/FOR cohort of patients initiating treatment with FP/FOR or changing from FP/SAL to FP/FOR and; 2) an FP/SAL cohort comprising patients initiating, or remaining on FP/SAL pMDI combination therapy...
August 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28732829/budesonide%C3%A2-%C3%A2-formoterol-delivered-via-spiromax-%C3%A2-for-the-management-of-asthma-and-copd-the-potential-impact-on-unscheduled-healthcare-costs-of-improving-inhalation-technique-compared-with-turbuhaler-%C3%A2
#10
A Lewis, S Torvinen, P N R Dekhuijzen, H Chrystyn, A Melani, Y Zöllner, K Kolbe, A T Watson, M Blackney, A Plich
BACKGROUND: Fixed-dose combinations of inhaled corticosteroids and long-acting β2 agonists are commonly used for the treatment of asthma and COPD. However, the most frequently prescribed dry powder inhaler delivering this medicine - Symbicort(®) (budesonide and formoterol, BF) Turbuhaler(®) - is associated with poor inhalation technique, which can lead to poor disease control and high disease management costs. A recent study showed that patients make fewer inhaler errors when using the novel DuoResp(®) (BF) Spiromax(®) inhaler, compared with BF Turbuhaler(®)...
August 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28732826/corrigendum-to-a-multicenter-randomized-double-blind-dose-ranging-study-of-glycopyrrolate-formoterol-fumarate-fixed-dose-combination-metered-dose-inhaler-compared-to-the-monocomponents-and-open-label-tiotropium-dry-powder-inhaler-in-patients-with-moderate-to
#11
Donald P Tashkin, Fernando J Martinez, Roberto Rodriguez-Roisin, Charles Fogarty, Mark Gotfried, Michael Denenberg, Gregory Gottschlich, James F Donohue, Chad Orevillo, Patrick Darken, Earl St Rose, Shannon Strom, Tracy Fischer, Michael Golden, Colin Reisner
No abstract text is available yet for this article.
August 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28720676/inhaler-training-delivered-by-internet-based-home-videoconferencing-improves-technique-and-quality-of-life
#12
Rachel M Thomas, Emily R Locke, Deborah M Woo, Ethan H K Nguyen, Valerie G Press, Troy A Layouni, Emily H Trittschuh, Gayle E Reiber, Vincent S Fan
BACKGROUND: COPD is common, and inhaled medications can reduce the risk of exacerbations. Incorrect inhaler use is also common and may lead to worse symptoms and increased exacerbations. We examined whether inhaler training could be delivered using Internet-based home videoconferencing and its effect on inhaler technique, self-efficacy, quality of life, and adherence. METHODS: In this pre-post pilot study, participants with COPD had 3 monthly Internet-based home videoconference visits with a pharmacist who provided inhaler training using teach-to-goal methodology...
July 18, 2017: Respiratory Care
https://www.readbyqxmd.com/read/28720336/baseline-symptom-score-impact-on-benefits-of-glycopyrrolate-formoterol-metered-dose-inhaler-in-copd
#13
Fernando J Martinez, Leonardo M Fabbri, Gary T Ferguson, Chad Orevillo, Patrick Darken, Ubaldo J Martin, Colin Reisner
BACKGROUND: The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) (an MDI fixed-dose of GFF 18/9.6 μg) over individual monocomponent MDIs included a cross-section of patients with moderate to very severe airflow limitation and a broad range of COPD symptoms...
July 16, 2017: Chest
https://www.readbyqxmd.com/read/28703592/interactions-between-%C3%AE-2-adrenoceptor-ligands-and-membrane-atomic-level-insights-from-magic-angle-spinning-nmr
#14
Si Yan, Duncan E Shaw, Linhong Yang, David A Sandham, Mark P Healy, John Reilly, Bing Wang
To understand the relationship between structural properties of the β2-adrenoceptor ligands and their interactions with membranes, we have investigated the location and distribution of five β2 agonists with distinct clinical durations and onsets of action (indacaterol, two indacaterol analogues, salmeterol and formoterol) in monounsaturated model membranes using magic angle spinning NMR to measure these interactions through both (1)H nuclear Overhauser enhancement (NOE) and paramagnetic relaxation enhancement (PRE) techniques...
August 4, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28702809/beta2-adrenergic-stimulation-increases-energy-expenditure-at-rest-but-not-during-submaximal-exercise-in-active-overweight-men
#15
Johan Onslev, Glenn Jacobson, Christian Narkowicz, Vibeke Backer, Anders Kalsen, Michael Kreiberg, Søren Jessen, Jens Bangsbo, Morten Hostrup
PURPOSE: β2-Agonists have been proposed as weight-loss treatment, because they elevate energy expenditure. However, it is unknown what effect β2-agonists have on energy expenditure in overweight individuals. Furthermore, the influence of β2-agonist R- and S-enantiomer ratio for the increased energy expenditure is insufficiently explored. METHODS: Nineteen males were included in the study of which 14 completed. Subjects were 31.6 (±3.5) years [mean (±95% CI)] and had a fat percentage of 22...
July 12, 2017: European Journal of Applied Physiology
https://www.readbyqxmd.com/read/28696794/the-effects-of-asthma-medications-on-reactive-oxygen-species-production-in-human-monocytes
#16
Ming-Kai Tsai, Yi-Ching Lin, Ming-Yii Huang, Min-Sheng Lee, Chang-Hung Kuo, Po-Lin Kuo, Ching-Hsiung Lin, Chih-Hsing Hung
OBJECTIVE: Asthma is a chronic inflammatory airway disease induced by many environmental factors. The inhalation of allergens and pollutants promote the reactive oxygen species (ROS) production leading to airway inflammation, hyper-responsiveness and remodeling in allergic asthma. The effects of asthma medications on ROS production are unclear. The present study investigated the anti-ROS effects of current asthma medications including inhaled corticosteroid (ICS; budesonide and fluticasone), leukotriene receptor antagonist (LTRA; montelukast), long acting β2 agonists (LABAs; salmeterol and formoterol) and a new extra-LABA (indacaterol)...
July 11, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28694692/health-resource-utilization-for-inpatients-with-copd-treated-with-nebulized-arformoterol-or-nebulized-formoterol
#17
Vaidyanathan Ganapathy, Michael D Stensland
OBJECTIVE: Arformoterol is the (R,R)-enantiomer of formoterol. Preclinical studies suggest that it is a stronger bronchodilator than the racemic (R,R/S,S)-formoterol; however, its potential clinical advantages have not been demonstrated. This study compared the length of stay (LOS), 30-day readmission rates, and doses of rescue medication administered in hospitalized patients with COPD who were treated with nebulized arformoterol or nebulized formoterol. METHODS: This retrospective analysis utilized data from Premier, Inc...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28683212/a-randomized-crossover-trial-evaluating-patient-handling-preference-and-ease-of-use-of-the-fluticasone-propionate-formoterol-breath-triggered-inhaler
#18
David Bell, Lucielle Mansfield, Mark Lomax
BACKGROUND: Appropriate inhaler selection is of fundamental importance in obstructive lung disease management. Key factors in device selection include a patient's capacity to operate a particular device and their preference for it. METHODS: This randomized, open-label, two-period, crossover study (NCT01739387) compared the ability of adolescent and adult patients with obstructive lung disease to correctly handle the fluticasone propionate/formoterol fumarate (FP/FORM; Flutiform(®)) pressurized metered-dose inhaler (pMDI) and FP/FORM K-haler(®), a novel breath-triggered inhaler (BTI), following a simple, standardized training regimen...
July 6, 2017: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/28637505/human-lung-and-monocyte-derived-macrophages-differ-with-regard-to-the-effects-of-%C3%AE-2-adrenoceptor-agonists-on-cytokine-release
#19
Tatiana Victoni, Hélène Salvator, Charlotte Abrial, Marion Brollo, Luis Cristovão Sobrino Porto, Vincent Lagente, Emmanuel Naline, Stanislas Grassin-Delyle, Philippe Devillier
BACKGROUND: β2-adrenoceptor agonists have been shown to reduce the lipopolysaccharide (LPS)-induced cytokine release by human monocyte-derived macrophages (MDMs). We compare the expression of β2-adrenoceptors and the inhibitory effect of formoterol and salmeterol on the LPS-induced release of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and a range of chemokines (CCL2, 3, 4, and IL-8) by human lung macrophages (LMs) and MDMs. METHODS: LMs were isolated from patients undergoing resection and MDMs were obtained from blood monocytes in the presence of GM-CSF...
June 21, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28626506/impact-of-nonadherence-to-inhaled-corticosteroid-laba-therapy-on-copd-exacerbation-rates-and-healthcare-costs-in-a-commercially-insured-us-population
#20
Jill R Davis, Bingcao Wu, David M Kern, Ozgur Tunceli, Kathleen M Fox, John Horton, Randall F Legg, Frank Trudo
BACKGROUND: Evidence of poor patient adherence to medications for chronic obstructive pulmonary disease (COPD) is well-documented, but its impact on disease exacerbation rates and associated healthcare costs remains unclear. OBJECTIVE: To assess the association between adherence levels to different inhaled corticosteroid/long-acting ß2-adrenergic agonist (LABA) and COPD exacerbation rates and costs in a commercially insured population. METHODS: In this observational cohort study, patients with COPD (aged ≥40 years) who were treatment-naïve to inhaled corticosteroid/LABA and were initiating budesonide plus formoterol or fluticasone plus salmeterol between March 1, 2009, and January 31, 2014, were identified in a national representative claims database and were followed for up to 12 months...
April 2017: American Health & Drug Benefits
keyword
keyword
15057
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"